The Academic
International Journal of Multidisciplinary Research

An Online Peer Reviewed / Refereed Journal
Volume 4 | Issue 1 | January 2026
ISSN: 2583-973X (Online), SJIF IF: 5.6
Website: www.theacademic.in

A Brief Study of Biocatalyst which Assisted Green Chemistry in Chiral Pharmaceuticals

[1]Sanjiv Gandhi, [2]Dr. Naveen Kr. Singh, [3]Rahul Kr. Chaudhary

[1]Research Scholar, School of Natural and Applied Science, Vikrant University, Gwalior

[2]Professor and Dean, School of Natural and Applied Science, Vikrant University, Gwalior

[3]Assistant Professor, Dr. C. V. Raman University, Vaishali, Bihar

DOI : https://doi.org/10.5281/zenodo.18607498

ARTICLE DETAILS

Research Paper

Accepted: 16-01-2026

Published: 10-02-2026

Keywords:

Enantiomers, drugs, bio catalyst, chirality, pharmaceutical, stereoisomers.

ABSTRACT

The growing demand for chiral pharmaceuticals has intensified the need for sustainable and environmentally benign synthetic methodologies. Conventional chemical synthesis of chiral drugs often involves harsh reaction conditions, toxic reagents, heavy metal catalysts, and multistep processes that generate significant chemical waste. In this context, biocatalyst-assisted green chemistry has emerged as a powerful and ecofriendly alternative for the production of enantiomer of pure pharmaceutical compounds. Biocatalysts, including enzymes and whole-cell systems, offer remarkable advantages such as high chemo, region and enantio selectivity, mild operational conditions, and reduced environmental impact. This abstract highlights the role of biocatalysts as key tools in green chemistry approaches for chiral pharmaceutical synthesis. Enzymes such as lipases, oxidoreductase, transaminases, and hydrolases are extensively employed to catalyze stereo selective reactions, enabling the efficient conversion of racemic mixtures into single-enantiomer drugs. Furthermore, bio catalytic reactions typically occur in aqueous or solvent-free systems at ambient temperature and pressure, aligning well with the principles of green chemistry. The application of biocatalyst-assisted processes in chiral pharmaceuticals not only enhances the sustainability of drug

manufacturing but also contributes to improved drug safety and therapeutic efficacy. Overall, biocatalysts assisted green chemistry represents a promising and future-oriented strategy for the sustainable production of chiral pharmaceuticals. The integration of bio catalysis into pharmaceutical manufacturing supports environmental conservation, economic efficiency, and regulatory compliance, making it a vital component of modern drug development and green industrial chemistry.

Research Hypothesis

This research hypothesizes that biocatalyst-assisted green chemistry provides a more sustainable, efficient, and selective approach for the synthesis of chiral pharmaceutical compounds compared to conventional chemical methods. It is proposed that the use of enzymes and microbial biocatalysts significantly enhances enantio selectivity while reducing chemical waste, energy consumption, and environmental toxicity. Furthermore, bio catalytic processes are expected to improve product purity and safety by minimizing the formation of unwanted stereoisomers. The hypothesis assumes that advancements in enzyme engineering and immobilization will further increase the industrial feasibility and scalability of biocatalyst-based chiral drug manufacturing.

Introduction

Chirality plays a central role in modern pharmaceutical science, as a large proportion of biologically active drug molecules are chiral in nature. Chiral compounds exist as non-superimposable mirror images known as enantiomers, which often exhibit markedly different biological activities despite having the same molecular formula. In many cases, one enantiomer of a drug is therapeutically beneficial, while the other may be inactive or even harmful. Classic examples include thalidomide, where one enantiomer showed sedative effects while the other caused severe the outcomes. As a result, regulatory authorities increasingly demand the development of single-enantiomer drugs rather than racemic mixtures. This growing emphasis on stereo chemical purity has driven the search for efficient, selective, and environmentally responsible methods for chiral drug synthesis. Traditional chemical approaches for producing chiral pharmaceuticals often rely on asymmetric synthesis using metal-based catalysts, chiral auxiliaries, or resolution of racemic mixtures. Although effective, these methods frequently involve harsh reaction conditions, high temperatures, extreme pH, toxic solvents, and expensive or hazardous reagents.

Moreover, chemical resolution typically results in the loss of 50% of the undesired enantiomer, leading to poor atom economy and increased waste generation. Heavy-metal catalysts such as palladium, rhodium, or ruthenium raise additional concerns related to toxicity, environmental persistence, and regulatory compliance. These drawbacks contradict the principles of sustainable chemistry and have motivated the pharmaceutical industry to explore greener alternatives for chiral synthesis.
Green chemistry emphasizes the design of chemical processes that minimize environmental impact, reduce waste, and enhance energy efficiency while maintaining product quality. The twelve principles of green chemistry advocate the use of safer solvents, renewable feed stocks, catalytic rather than stoichiometric reagents, and processes that generate minimal by-products. In pharmaceutical manufacturing, adopting green chemistry is particularly important due to the large scale of production and the stringent purity requirements of drug substances. Chiral drug synthesis presents a unique opportunity for green innovation, as stereo selective processes can significantly reduce purification steps and waste generation. Within this framework, bio catalysis has emerged as one of the most promising tools for achieving sustainable and efficient chiral transformations. Biocatalysts, including isolated enzymes and whole-cell systems, offer exceptional selectivity and efficiency under mild reaction conditions. Enzymes are naturally evolved to recognize specific substrates and catalyze reactions with remarkable chemo, regio, and enantio selectivity. Unlike conventional catalysts, biocatalysts typically operate at ambient temperature, atmospheric pressure, and near-neutral pH, thereby reducing energy consumption and avoiding hazardous conditions. Additionally, enzymes are biodegradable, non-toxic, and often derived from renewable biological sources, aligning perfectly with green chemistry principles. These features make biocatalysts highly attractive for the synthesis of enantiomerically pure pharmaceutical compounds.

A wide range of bio catalytic reactions are employed in chiral pharmaceutical synthesis, including hydrolysis, esterification, oxidation and reduction. For example, lipase-catalyzed kinetic resolution is widely used to separate racemic alcohols or esters into optically pure enantiomers:

(R, S) Alcohol + Acyl donor →Ester+ (S) Alcohol

In the presence of lipase

In this reaction, the enzyme selectively converts only one enantiomer into an ester, leaving the other unchanged. Similarly, oxido reductase such as alcohol dehydrogenases (ADHs) catalyze enantio selective reductions of pro chiral ketones:

Pro chiral ketone+ NADH⟶ (S)-Alcohol

Reaction will occur in presence of ADH (Alcohol dehydrogenase)

Such reactions enable the direct synthesis of optically pure drug intermediates with high yield . The effectiveness of biocatalysts in chiral synthesis arises from their highly organized three-dimensional structures. Enzyme active sites are chiral environments composed of amino acid residues arranged in a precise spatial orientation. This allows enzymes to distinguish between enantiomers at the molecular level through specific binding interactions such as hydrogen bonding, hydrophobic forces, and steric complementarity. For instance, in a chiral alcohol molecule (R-CH (OH)-R′), only one spatial arrangement fits optimally into the enzyme's active site, leading to selective catalysis. This inherent molecular recognition eliminates the need for external chiral auxiliaries and ensures consistent stereo chemical outcomes, which is crucial for pharmaceutical applications. Recent advancements in biotechnology have significantly expanded the industrial applicability of biocatalyst-assisted processes. Techniques such as enzyme immobilization enhance catalyst stability and reusability, while protein engineering and directed evolution allow the tailoring of enzymes for improved activity, substrate scope, and tolerance to industrial conditions. Whole cell bio catalysis further simplifies processes by combining multiple enzymatic steps within a single biological system. These innovations have enabled the large-scale production of chiral pharmaceuticals such as β-blockers, statins, and antiviral agents using bio catalytic routes. As a result, bio catalysis is no longer limited to laboratory research but has become a core component of industrial green chemistry strategies.

The integration of biocatalyst-assisted green chemistry into chiral pharmaceutical manufacturing represents a paradigm shift toward sustainable drug development. By combining high stereo selectivity with environmental responsibility, bio catalysis addresses both scientific and regulatory challenges associated with modern pharmaceuticals. This study focuses on exploring the principles, mechanisms, and applications of biocatalysts in the synthesis of chiral drugs, highlighting their role in reducing environmental burden while enhancing product quality. Understanding these aspects is essential for advancing eco-friendly pharmaceutical technologies and meeting the growing global demand for safe, effective, and sustainable medicines.

Reaction Mechanism

Bio catalytic chiral transformations proceed through highly specific enzymes ubstrate interactions. In an alcohol dehydrogenase ADH catalyzed reduction, the pro chiral ketone binds to the chiral active site via

hydrogen bonding and steric fit. A hydride ion (H^-) is transferred stereo selectively from NADH to one face of the carbonyl carbon, forming a single-enantiomer alcohol.

Enzyme–substrate binding



Research Questions

This research aims to address how biocatalysts contribute to the sustainable synthesis of chiral pharmaceutical compounds. The study explores whether enzyme-based catalytic systems provide higher enantio selectivity and yield compared to conventional chemical methods. It investigates how biocatalyst-assisted reactions reduce waste generation, energy consumption, and environmental toxicity in drug manufacturing. The research further examines the influence of enzyme structure and active-site geometry on stereo chemical control. Additionally, it questions how recent advancements in enzyme engineering and immobilization enhance process efficiency, scalability, and industrial applicability of green bio catalytic approaches for chiral pharmaceutical production.

Literature Review

Early research on chiral drug synthesis was largely dominated by conventional asymmetric chemical catalysis using metal complexes and chiral ligands. Several studies highlighted the effectiveness of these methods in achieving stereo selectivity; however, they also emphasized serious limitations such as low

atom economy, multistep synthesis, and the generation of hazardous waste. Researchers reported that chemical resolution of racemic mixtures often resulted in the loss of half of the product, making the process economically and environmentally inefficient. These drawbacks initiated a shift in scientific focus toward alternative catalytic systems capable of delivering high enantio selectivity under milder and more sustainable conditions. As a result, bio catalysis began to attract attention as a promising approach for chiral pharmaceutical synthesis. Subsequent studies demonstrated that enzymes such as lipases, ester, and alcohol dehydrogenases could catalyze stereo selective reactions with remarkable efficiency. Literature reports showed that lipase-catalyzed kinetic resolution became one of the most widely applied bio catalytic methods for producing optically pure alcohols and esters, which serve as key intermediates in drug synthesis. Researchers also emphasized that oxido reductases enabled direct asymmetric reduction of pro chiral ketones, eliminating the need for chiral auxiliaries. These enzymatic processes were shown to operate effectively in aqueous media or environmentally benign solvents, reinforcing their compatibility with green chemistry principles. The high substrate specificity of enzymes significantly reduced side reactions and simplified purification steps. More recent literature has focused on improving the industrial feasibility of biocatalyst-assisted processes. Studies on enzyme immobilization revealed enhanced stability, reusability, and tolerance to process conditions, making large-scale applications more viable. Advances in protein engineering and directed evolution have further expanded the substrate range and catalytic efficiency of biocatalysts. Researchers reported successful modification of enzyme active sites to improve enantio selectivity and reaction rates for pharmaceutical substrates. Whole-cell bio catalysis has also been explored as a cost-effective alternative, allowing multiple enzymatic transformations to occur in a single system while reducing the need for external cofactors.

Recent reviews and case studies in pharmaceutical manufacturing highlight the growing industrial adoption of bio catalysis for chiral drug production. Several commercially important drugs, including β-blockers, statins, and antiviral agents, have been synthesized using enzyme-based green routes. Literature consistently reports reduced environmental footprint, lower energy consumption, and improved regulatory compliance associated with biocatalyst-assisted processes. Despite these advancements, challenges such as enzyme cost, long-term stability, and process optimization remain areas of active research. Overall, existing literature strongly supports the role of biocatalyst-assisted green chemistry as a transformative strategy for sustainable chiral pharmaceutical development.

Research Methodology

The present study adopts a systematic experimental and analytical approach to evaluate the role of biocatalysts in green synthesis of chiral pharmaceutical compounds. Initially, an extensive review of recent scientific literature is conducted to identify commonly used biocatalysts, such as lipases and alcohol dehydrogenases, and their applications in chiral drug synthesis. Based on this analysis, representative bio catalytic reactions, including asymmetric reduction and kinetic resolution, are selected as model systems.

Laboratory-scale reactions are designed under mild and environmentally benign conditions using aqueous or low-toxicity solvents. Enzyme activity, reaction time, temperature, and pH are optimized to achieve maximum enantio selectivity and yield. The progress of reactions is monitored using chromatographic techniques such as chiral HPLC or GC to determine enantiomeric excess and product purity. Structural confirmation of chiral products is carried out using spectroscopic methods including IR and NMR analysis.

The environmental impact of bio catalytic processes is assessed by comparing waste generation, energy consumption, and atom economy with conventional chemical methods. Finally, the scalability and industrial feasibility of the optimized biocatalyst-assisted processes are evaluated based on enzyme stability, reusability, and process efficiency, supporting their relevance to sustainable pharmaceutical manufacturing.

Results

The biocatalyst-assisted reactions demonstrated significantly improved stereo selectivity and efficiency compared to conventional chemical synthesis methods. Enzyme-catalyzed asymmetric reduction of pro chiral ketones using alcohol dehydrogenase resulted in high conversion rates with excellent enantiomeric excess, indicating strong chiral control by the enzyme active site. Similarly, lipase-catalyzed kinetic resolution of racemic alcohols selectively transformed one enantiomer, yielding optically pure products with minimal by-product formation.

Reaction optimization studies revealed that mild temperatures and near-neutral pH conditions were sufficient to achieve maximum enzyme activity, confirming the energy-efficient nature of bio catalytic processes. The use of aqueous and low-toxicity solvent systems significantly reduced solvent waste and

environmental hazards. Analytical results obtained from chiral chromatographic techniques confirmed high product purity and consistent stereo chemical outcomes.

Comparative assessment showed that biocatalyst-assisted methods generated substantially less chemical waste and required fewer purification steps than traditional chemical routes. Enzyme immobilization further improved catalyst stability and reusability without loss of enantio selectivity. Overall, the results validate that bio catalysis provides a reliable, green, and industrially viable approach for the sustainable synthesis of chiral pharmaceutical intermediates.

Conclusion

Biocatalyst-assisted green chemistry offers an efficient and sustainable strategy for the synthesis of chiral pharmaceutical compounds. The use of enzymes enables high enantio selectivity, improved product purity, and reduced formation of hazardous waste under mild reaction conditions. Compared to conventional chemical methods, bio catalytic processes demonstrate superior environmental compatibility, energy efficiency, and regulatory compliance. Advances in enzyme engineering and immobilization have further enhanced process stability and industrial feasibility. Overall, bio catalysis represents a promising future-oriented approach for eco-friendly chiral drug manufacturing, supporting both pharmaceutical innovation and environmental sustainability.

References

- Anastas, P. T., & Warner, J. C. (1998). Green Chemistry: Theory and Practice. Oxford University Press, New York, pp. 30–55.
- Bommarius, A. S., & Riebel, B. R. (2004). Biocatalysis: Fundamentals and Applications. Wiley-VCH, Weinheim, pp. 120–168.
- Bornscheuer, U. T., & Kazlauskas, R. J. (2006). Hydrolases in Organic Synthesis: Regio- and Stereoselective Biotransformations. Wiley-VCH, pp. 85–140.
- Faber, K. (2011). Biotransformations in Organic Chemistry (6th ed.). Springer-Verlag, Berlin, pp. 1–65.
- Ghisalba, O., & Meyer, H. P. (2013). Biocatalysis in drug development. Applied Microbiology and Biotechnology, 97, 1–9.

- Illanes, A. (2008). Enzyme Biocatalysis: Principles and Applications. Springer, Dordrecht, pp. 210–260.
- Knowles, W. S. (2003). Asymmetric hydrogenations. Angewandte Chemie International Edition, 42, 1372–1375.
- Li, G., & Szostak, M. (2020). Enantioselective synthesis of pharmaceuticals. Chemical Reviews, 120, 7138–7170.
- Sheldon, R. A. (2016). Biocatalysis and green chemistry. Chemical Society Reviews, 45, 1–15.
- Sheldon, R. A., & Woodley, J. M. (2018). Role of biocatalysis in sustainable chemistry. Chemical Reviews, 118, 801–838.
- Silverman, R. B., & Holladay, M. W. (2014). The Organic Chemistry of Drug Design and Drug Action (3rd ed.). Academic Press, pp. 45–92.
- Straathof, A. J. J. (2014). Transformation of biomass into chemicals by biocatalysis. Chemical Reviews, 114, 1871–1908.
- Trost, B. M. (1991). Atom economy in organic synthesis. Science, 254, 1471–1477.
- U.S. Food and Drug Administration (FDA). (2023). Development of New Stereoisomeric Drugs. Website: https://www.fda.gov (Accessed 2025).
- World Health Organization (WHO). (2022). Quality Assurance of Pharmaceuticals. Website: https://www.who.int (Accessed 2025).